Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33799470

Citations 72

Authors

Shirin Hafezi

Mohamed Rahmani

Affiliations

Soon will be listed here.

Abstract

The major form of cell death in normal as well as malignant cells is apoptosis, which is a programmed process highly regulated by the BCL-2 family of proteins. This includes the antiapoptotic proteins (BCL-2, BCL-XL, MCL-1, BCLW, and BFL-1) and the proapoptotic proteins, which can be divided into two groups: the effectors (BAX, BAK, and BOK) and the BH3-only proteins (BIM, BAD, NOXA, PUMA, BID, BIK, HRK). Notably, the BCL-2 antiapoptotic proteins are often overexpressed in malignant cells. While this offers survival advantages to malignant cells and strengthens their drug resistance capacity, it also offers opportunities for novel targeted therapies that selectively kill such cells. This review provides a comprehensive overview of the extensive preclinical and clinical studies targeting BCL-2 proteins with various BCL-2 proteins inhibitors with emphasis on venetoclax as a single agent, as well as in combination with other therapeutic agents. This review also discusses recent advances, challenges focusing on drug resistance, and future perspectives for effective targeting the Bcl-2 family of proteins in cancer.

Citing Articles

A Comparative Study of Bcl-2 Expression in Oral Leukoplakia with Dysplasia, Verrucous Carcinoma, and Oral Squamous Cell Carcinoma.

Roy B, Saxena S, Tripathi N, Sharma M, Rana D, Pramukh N J Pharm Bioallied Sci. 2025; 16(Suppl 4):S3936-S3938.

PMID: 39927061 PMC: 11805061. DOI: 10.4103/jpbs.jpbs_1190_24.

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia.

Li J, Ye C, Li H, Li J Cancer Biol Ther. 2025; 26(1):2457777.

PMID: 39862423 PMC: 11776473. DOI: 10.1080/15384047.2025.2457777.

The Protective Effect of Nimodipine in Schwann Cells Is Related to the Upregulation of LMO4 and SERCA3 Accompanied by the Fine-Tuning of Intracellular Calcium Levels.

Leisz S, Fritzsche S, Strauss C, Scheller C Int J Mol Sci. 2025; 26(2.

PMID: 39859578 PMC: 11765607. DOI: 10.3390/ijms26020864.

Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia.

Kawakatsu R, Tadagaki K, Yamasaki K, Kuwahara Y, Yoshida T Diseases. 2025; 13(1).

PMID: 39851474 PMC: 11764158. DOI: 10.3390/diseases13010010.

Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.

Zapata Dongo R, Fontana D, Mologni L, Faya Castillo J, Infante Varillas S PLoS One. 2025; 20(1):e0308747.

PMID: 39836700 PMC: 11750102. DOI: 10.1371/journal.pone.0308747.

References

Campbell C, Lee J, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B . The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 2010; 116(9):1433-42. DOI: 10.1182/blood-2009-12-258095. View

Testa U, Riccioni R . Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007; 92(1):81-94. DOI: 10.3324/haematol.10279. View

Uren R, OHely M, Iyer S, Bartolo R, Shi M, Brouwer J . Disordered clusters of Bak dimers rupture mitochondria during apoptosis. Elife. 2017; 6. PMC: 5302884. DOI: 10.7554/eLife.19944. View

Reyna D, Garner T, Lopez A, Kopp F, Choudhary G, Sridharan A . Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell. 2017; 32(4):490-505.e10. PMC: 5793879. DOI: 10.1016/j.ccell.2017.09.001. View

Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G . Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res. 2016; 22(17):4440-51. PMC: 5010519. DOI: 10.1158/1078-0432.CCR-15-3057. View

Hughes M, Landsburg D, Rubin D, Schuster S, Svoboda J, Gerson J . Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. Clin Lymphoma Myeloma Leuk. 2019; 19(12):791-798. DOI: 10.1016/j.clml.2019.09.612. View

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

Bertino E, Gentzler R, Clifford S, Kolesar J, Muzikansky A, Haura E . Phase IB Study of Osimertinib in Combination with Navitoclax in -mutant NSCLC Following Resistance to Initial Therapy (ETCTN 9903). Clin Cancer Res. 2020; 27(6):1604-1611. PMC: 7976451. DOI: 10.1158/1078-0432.CCR-20-4084. View

Garrison S, Jeffers J, Yang C, Nilsson J, Hall M, Rehg J . Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008; 28(17):5391-402. PMC: 2519737. DOI: 10.1128/MCB.00907-07. View

10.

Chan S, Thomas D, Corces-Zimmerman M, Xavy S, Rastogi S, Hong W . Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178-84. PMC: 4406275. DOI: 10.1038/nm.3788. View

11.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

12.

Jonas B, Pollyea D . How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019; 33(12):2795-2804. DOI: 10.1038/s41375-019-0612-8. View

13.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

14.

Rahmani M, Aust M, Attkisson E, Williams Jr D, Ferreira-Gonzalez A, Grant S . Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 2012; 119(25):6089-98. PMC: 3383017. DOI: 10.1182/blood-2011-09-378141. View

15.

Zhang J, Huang K, ONeill K, Pang X, Luo X . Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Cell Death Dis. 2016; 7:e2266. PMC: 5143395. DOI: 10.1038/cddis.2016.167. View

16.

Qian S, Wang W, Yang L, Huang H . Structure of transmembrane pore induced by Bax-derived peptide: evidence for lipidic pores. Proc Natl Acad Sci U S A. 2008; 105(45):17379-83. PMC: 2582298. DOI: 10.1073/pnas.0807764105. View

17.

Chen K, Gilabert-Oriol R, Bally M, Leung A . Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Pharm Res. 2019; 36(9):125. PMC: 6591181. DOI: 10.1007/s11095-019-2654-z. View

18.

Schimmer A, OBrien S, Kantarjian H, Brandwein J, Cheson B, Minden M . A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008; 14(24):8295-301. DOI: 10.1158/1078-0432.CCR-08-0999. View

19.

Um H . Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 2015; 7(5):5193-203. PMC: 4868680. DOI: 10.18632/oncotarget.6405. View

20.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View